Palivizumab Biosimilar, N297A Mutant
$375.00
Palivizumab Biosimilar, N297A Mutant. Palivizumab biosimilar CHO stable cell line is available for licensing to manufacture the palivizumab biosimilar protein. The research grade palivizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | C021P.NA |
|---|---|
| Product Name | Palivizumab Biosimilar, N297A Mutant |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | Anti-RSV Humanized Monoclonal Antibody |
| Summary | Recombinant Humanized IgG1 Monoclonal Antibody. |
| Isotype | Human IgG1 kappa. |
| Source/Host | The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line. |
| Specificity/Sensitivity | The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus). |
| Form Of Antibody | 0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives. |
| Endotoxin | < 1 EU per 1 mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The Palivizumab Biosimilar, N297A Mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | Palivizumab biosimilar CHO stable cell line is available for licensing to manufacture the palivizumab biosimilar protein.The research grade palivizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card. |
Description
C021P.NA: Palivizumab Biosimilar, N297A Mutant
Recombinant Humanized IgG1 Monoclonal Antibody.
Background
Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.
Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)
Please remember our product information: Palivizumab Biosimilar, N297A Mutant: C021P.NA Syd Labs
Additional information
| Ship from Country | USA |
|---|---|
| Size | 0.5 mg |
